What does CUSIP 558868105 represent in this 13F holders report?

CUSIP 558868105 is the security identifier for MDGL - MADRIGAL PHARMACEUTICALS, INC. - Common Stock used to aggregate holder disclosures.

How many institutions held MDGL - MADRIGAL PHARMACEUTICALS, INC. - Common Stock in Q2 2019?

115 institutional investors reported MDGL - MADRIGAL PHARMACEUTICALS, INC. - Common Stock for Q2 2019. Use the holders table for investor-level position and value details.

MADRIGAL PHARMACEUTICALS, INC. - Common Stock (MDGL)

CUSIP: 558868105

Q2 2019 13F Holders as of 30 Jun 2019

Security type / class: Equity / Common Stock
Total 13F shares: 9,609,887
Total 13F value: $1,007,125,218
Share change: +181,512
Put/Call ratio: 115%
SEC-reported price per share: $104.81
Number of holders: 115
Value change: +$10,337,419
Number of buys: 68
Number of sells: 48
Shares outstanding: 23,203,174

Security key

558868105

Report period

Q2 2019

Institutions

115

Top holders

MDGL full security history Ownership snapshot Full 13F holder table MADRIGAL PHARMACEUTICALS, INC. SEC filings MADRIGAL PHARMACEUTICALS, INC. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Ownership snapshot

Top reported holders of MDGL - MADRIGAL PHARMACEUTICALS, INC. - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader

Capital Research Global I...

Disclosed value leader

Capital Research Global I...

Comparable rows

15/15

Latest evidence

31 Mar 2019

13F Lead comparable stake: 7.2% Showing 1-6 of 15 holder rows.

Quick read

Capital Research Global Investors leads the comparable SEC ownership view at 7.2%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Capital Research Global Investors's linked filing trail.

Comparable ownership Top 5

Capital Research Global Investors 7.2%

BAKER BROS. ADVISORS LP 5%

HealthCor Management, L.P. 3.8%

VANGUARD GROUP INC 3.4%

STATE STREET CORP 2.4%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows

Holder	Evidence	Ownership %	Position	12M Net Δ	As of
Capital Research Global Investors	13F Company 13F	7.2%	$208,489,000 1,664,452 shares	—	31 Mar 2019
BAKER BROS. ADVISORS LP	13F Company 13F	5%	$146,464,000 1,169,278 shares	—	31 Mar 2019
HealthCor Management, L.P.	13F Company 13F	3.8%	$111,731,000 891,990 shares	—	31 Mar 2019
VANGUARD GROUP INC	13F Company 13F	3.4%	$97,862,000 781,276 shares	—	31 Mar 2019
STATE STREET CORP	13F Company 13F	2.4%	$70,943,000 566,362 shares	—	31 Mar 2019
BlackRock Finance, Inc.	13F Company 13F	2.3%	$65,454,000 522,540 shares	—	31 Mar 2019

How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q2 2019

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions

115

9,609,887

Rows available

115

Investor	Option	Weight %	Change %	SEC-reported value	* Price	Shares	Share Change	Activity	Report Period

^* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q2 2019 vs Q1 2019 Across Filers

Q1 2019 holders

133

Q2 2019 holders

115

Holder diff

-18

Investor	Q1 2019 Shares	Q2 2019 Shares	Share Diff	Share Chg %	Q1 2019 value	Q2 2019 value	Value change	Value Chg %